The massive EPS beat is likely to drive a strong initial gap-up, but the Q3 guidance for a sharp margin contraction (adjusted EBITDA margin falling from 10.9% to ~6.75%) creates a significant headwind. Traders should watch for whether the stock can hold gains after the initial reaction, as the sequential revenue decline and margin compression suggest the Q2 beat was partly driven by non-recurring items (labor disruption billing true-ups).
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 7 $36.00entry
- T+1 · 3mo ago +1.67%α +1.70% · $36.60
- T+5 · 3mo ago −4.17%α −4.57% · $34.50
- T+20 · 2mo ago −6.11%α −5.71% · $33.80
- T+60 · 15d ago +30.86%α +33.13% · $47.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AMN Healthcare reported Q2 2026 adjusted EPS of $0.77, massively beating the $0.19 consensus, on revenue of $673M vs. $628.4M consensus. The strong beat was driven by travel nurse and allied growth, but Q3 guidance implies a sharp sequential decline in adjusted EBITDA margin to 6.5-7.0% from Q2's 10.9%, tempering the headline beat.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $673M beat consensus of $628.4M and grew 2% YoY.
- Adjusted diluted EPS of $0.77 beat consensus of $0.19 by 307.8%.
- GAAP diluted EPS was $0.53, compared to a ($3.02) loss in Q2 2025.
- Nurse and Allied Solutions revenue grew 11% YoY to $422M.
- Q3 2026 revenue guidance of $640-655M implies 1-3% YoY growth.
- Q3 2026 adjusted EBITDA margin guidance of 6.5-7.0% is down sharply from Q2's 10.9%.
- Cash balance was $362M with a leverage ratio of 1.5x.
- Operating cash flow was negative ($190M) in Q2 due to return of client deposits from prior labor disruption events.
Financial Impact
EPS beat by $0.58 vs consensus; revenue beat by $44.6M; Q3 guidance implies adjusted EBITDA of ~$42-46M vs Q2's $73M
Risk Factors
- Q3 guidance implies a steep sequential decline in profitability (adjusted EBITDA margin from 10.9% to ~6.75%).
- Operating cash flow was negative $190M in Q2 due to client deposit returns.
- Nurse and Allied revenue fell 63% sequentially as large labor disruption events normalized.
- Technology and Workforce Solutions segment revenue declined 15% YoY.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302845249 |
Track record
11 reports on AMN
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +47.16% at T+60 after the Aug 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $38.48 Now $39.64 +3.01% settles Nov 23
- Nov 5, 202611d ago 8-K Mixed 6/10 No price data
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $36.19 to $38.02 Now $39.64 −9.53% ▼ −5.06% −2.46% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $46.94 to $47.42 Now $39.64 −15.55% ▲ +1.02% +5.75% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 4/10 Entry $32.44 to $35.32 Now $39.64 +22.19% ▲ +8.88% +9.32% vs SPY
- Aug 6, 202614w ago Press Release Mixed 6/10 Viewing Entry $36.00 to $34.50 Now $39.64 +10.11% ▼ −4.17% −4.57% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $30.79 to $32.38 Now $39.64 +28.74% ▲ +5.16% +4.73% vs SPY
- May 4, 202628w ago 8-K Neutral 2/10 Entry $20.72 to $30.27 Now $39.64 +91.31% ▲ +46.09% +43.15% vs SPY
- Apr 9, 202631w ago Press Release Neutral 1/10 Entry $18.49 Now $39.64 +114.39% No price data
- Mar 18, 202634w ago DEFA14A Neutral 3/10 Entry $17.93 to $18.89 Now $39.64 +121.08% ▲ +5.35% +6.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers